Masakazu Hirakawa MD, Presenter: Nothing to Disclose

Yoshiki Asayama MD, Abstract Co-Author: Nothing to Disclose

Akihiro Nishie MD, Abstract Co-Author: Nothing to Disclose

Yasuhiro Ushijima MD, Abstract Co-Author: Nothing to Disclose

Kimitaka Miyajima MD, PhD, Abstract Co-Author: Nothing to Disclose

Hiroshi Honda MD, Abstract Co-Author: Nothing to Disclose

The aim of this retrospective study is to compare the localcontrol effects of microballoon-occluded transarterial chemoembolization (B-TACE) with miriplatin (MPT) and those of conventional TACE with epirubicin (EPIR) for hepatocellular carcinoma (HCC)

Sixty-five HCC cases were treated with TACE using EPIR or MPT. Forty patients (25 men, 15 women; mean age, 73.4 years) were treated using B-TACE with MPT (the MPT-B-TACE group), and 25 patients (15 men, 10 women; mean age, 72.2 years) were treated using TACE with EPIR (the EPIR-TACE group). The local control rates (modified Response Evaluation Criteria in Solid Tumors [mRECIST]), time to local recurrence (Kaplan-Meier and log-rank tests), and adverse events (AEs) were evaluated. Statistical analyses were conducted to evaluate the relationship between the patient’s characteristics and local recurrence after MPT-B-TACE using Pearson's Chi-squared test. Multivariate logistic regression analysis was also performed.

There were no significant differences in patient’s characteristics between the groups. The overall AE incidence did not significantly differ between the groups. According to the mRECIST, the objective response rate including complete and partial responses, in the MPT-B-TACE group (92%) was significantly higher than that in the EPIR-TACE group (76%). Overall, local recurrences in the MPT-B-TACE group were significantly lower than in the EPIR-TACE group (p < 0.05). Excluding multiple HCC cases, the local recurrence rate in the MP T-B-TACE group was significantly lower than in the EPIR-TACE group (p < 0.05). Local recurrence after MPT-B-TACE was recognized in the 35% patients in the follow-up periods. Tumor size larger than 2cm and tumor number more than three HCCs were significant key factors in the local recurrence after MPT-B-TACE.  

MPT-B-TACE was associated with a higher objective response rate and lower local recurrence rate than EPIR-TACE, and both showed similar adverse effects. Tumor size larger than 2cm and tumor number more than three HCCs were risk factors of the local recurrence after MPT-B-TACE.

B-TACE with miriplatin may have great potential advantages in comparison with conventional TACE with epirubicin, and might constitute a novel therapeutic option for unresectable HCC.

Hirakawa, M, Asayama, Y, Nishie, A, Ushijima, Y, Miyajima, K, Honda, H, Local Control Effect of Microballoon-occluded Transarterial Chemoembolization with Miriplatin for Hepatocellular Carcinoma: A Retrospective Comparison of Conventional TACE with Epirubicin.  Radiological Society of North America 2014 Scientific Assembly and Annual Meeting, - ,Chicago IL. http://archive.rsna.org/2014/14007005.html